CD274 and non-small cell lung carcinoma: Of note, the combination of a plasma microRNA-signature classifier (MSC) and PD-L1 showed the more potent predictive value and could identify NSCLC patients with the worst clinical outcome (0% one-year PFS and OS subgroup with no favorable markers) in immunotherapy (100).